Phase I/II Study of NGGT001 Gene Therapy for Bietti Crystalline Dystrophy
{{output}}
Purpose: To evaluate the safety and preliminary functional outcomes of NGGT001 gene therapy across dose cohorts in adults with Bietti crystalline dystrophy (BCD) with relatively preserved vision. ... ...
